Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end
Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end losses of $50.6 million, compared to $2 million the year before. The South San Francisco, CA, company attributed these results to increased operating expenses to support its R&D and commercialization activities for Bexxar, the cancer therapy product Coulter is developing with SmithKline Beecham for the treatment of non-Hodgkins lymphoma. Coulter ended the year with cash assets of $82 million.
In other Coulter news, the firm has received a composition patent from the U.S. Patent and Trademark Office. Arising from Coulters work on Bexxar, the patent covers radiolabeled monoclonal antibodies for the treatment of B-cell lymphomas, and strengthens Coulters position in the field of radioimmunotherapy, according to president and CEO Michael Bigham.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.